Zhejiang Hisun Pharmaceutical Co., Ltd. Class ASSE: 600267

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Company's Proposed Selection in the National Centralized Drug Procurement

Aug 4, 2026 · Issued by Zhejiang Hisun Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on the Company's Proposed Selection in the National Centralized Drug Procurement

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of Fludarabine Phosphate Injection of the Wholly-owned SubsidiaryJul 25
"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Jul 21

All Zhejiang Hisun Pharmaceutical Co., Ltd. Class A news releases